Navigation Links
The Japanese Cancer Association and Debiopharm Group™ Present Doctors Arakawa and Kurokawa With the 2011 'JCA-Mauvernay Award' for Their Innovative and Outstanding Research in the Field of Cancer
Date:10/5/2011

3 is also a guardian of mitochondria.

Dr Mineo Kurokawa works in the department of Hematology and Oncology at the Graduate School of Medicine. For 20 years, he has studied the mechanisms of malignant transformation of hematopoietic stem cells (multipotent stem cells that give rise to all blood lineages) in order to elucidate the pathogenesis of blood malignancies. He focused on the role of transcription factors associated with human leukaemia. For instance he revealed the transforming activity of EVI1, a protein frequently activated in human leukaemia and elucidated its' functions that are involved in the prevention of cell death.

Through his pursuit of the pathogenetic significance of deregulated transcription factors in leukaemia, Dr Kurokawa has consistently contributed to the understanding of a mechanistic basis of leukaemia development and the identification of novel therapeutic targets of human haematological malignancies.

"We are proud to reward these very talented and inspiring scientists for their hard work and accomplishments. The jury's decision to nominate them was unanimous," said Rolland-Yves Mauvernay, President and founder of Debiopharm Group™. "We wish them a lot of luck for the future hoping their work will lead to major medical developments eventually benefiting the patients in the years to come."

About Debiopharm Group™

Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III, as well as earlier stage candidates. It develops its products for global registration and maximum commercial potential. The products are out-licensed to pharmaceutical partners for s
'/>"/>

SOURCE The Debiopharm Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Circassia Acquires North American and Japanese Rights to Dopexamine
2. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
3. Japanese Cancer Association and Debiopharm Honour Japanese Research
4. Australian Authorities (TGA) First to Grant Final Product Approval for Intercells Vaccine to Prevent Japanese Encephalitis
5. GenVault Opens Japanese Subsidiary to Better Address Global Biobanking Market Growth
6. Boston Scientific Announces Japanese Approval for TAXUS(R) Liberte(R) Drug-Eluting Stent System
7. Forward-Thinking Patient Recruitment Company Poised to Create Bridges Between Japanese Clinical R&D Industry and Global Clinical Trial Marketplace
8. Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis
9. Intercell to Host Conference Call and Webcast Today on FDA Approval of IXIARO(R) Japanese Encephalitis Vaccine
10. Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis
11. SynCo Bio Partners Enters the Japanese Market as it Signs its First Agreement With a Japanese Pharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... ... July 02, 2015 , ... In’Tech Medical SAS ( http://www.intech-medical.com ... announced today the acquisition of Turner Medical, Inc ., thus becoming a ... to the Spine Industry. The acquisition of Turner Medical ideally supplements In’Tech Medical’s ...
(Date:7/1/2015)... 2015   Decision Resources Group finds ... Otezla are its oral administration, alternative mechanism of ... surveyed rheumatologists. Otezla was the first oral therapy ... active psoriatic arthritis in the United ... includes conventional oral treatments including disease-modifying antirheumatic drugs ...
(Date:7/1/2015)... 1, 2015   Neuraltus Pharmaceuticals, Inc. , a ... groundbreaking drugs to treat neurodegenerative diseases such as ... Robert G. Miller , M.D., Director of the Forbes ... Pacific Medical Center in San Francisco, has been awarded ... million to help fund a Phase 2 clinical ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... A newly ... new ideas to lower the barriers to innovation in life sciences R&D. The Pistoia ... to two cash prizes of US$15,000 and a period of expert mentorship from a ...
Breaking Biology Technology:In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3
... The Alfred E. Mann Foundation for,Biomedical Engineering (AEMFBE), ... establish university-based commercialization-,enablement institutes at elite universities, designed to ... announced the launch of,a Web site ( http://www.mannfbe.org ). ... the web site include: , ...
... BNVI ), a pharmaceutical company focused on the discovery and,development of ... announced that Isaac Cohen, Chairman and CEO of Bionovo, will be,presenting ... Health,Care Conference at 8 a.m. EST on December 3, 2008. ... New York City. , The ...
... Dec. 2 The Patient,Advocate Foundation (PAF), with support ... launch of the Lymphedema CareLine (LCL). PAF, through,its MedCare ... provide information and assistance to breast cancer,patients who are ... such as,lymphedema (swelling due to blockage in the lymphatic ...
Cached Biology Technology:Alfred Mann Foundation for Biomedical Engineering Launches New Web Site Designed to Help University Researchers Bring Biomedical Advances to Market 2Bionovo to Present at the Piper Jaffray Healthcare Conference 2New Program Offers Breast Cancer Clinicians and Patients Support for Pre-Operative Clinical Assessment and Ongoing Surveillance of Lymphedema 2New Program Offers Breast Cancer Clinicians and Patients Support for Pre-Operative Clinical Assessment and Ongoing Surveillance of Lymphedema 3
(Date:6/29/2015)... , June 24, 2015 ... addition of the "Latin America Biomedical Sensors Market ... their offering. The Latin America Biomedical Sensors ... a CAGR of 2.04% over the period 2014-2020 ... are adaptable to the genetic formulation of each individual. ...
(Date:6/25/2015)... 2015 According to a ... & Area), Technology, Material (Optical Prism, Piezoelectric, Capacitive ... & Others) & Geography - Global Forecast to ... market is expected to reach $14,500.07 Million by ... Browse 76 market Tables and 109 Figures ...
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., ... patent by the United States Patent and Trademark Office ... This process leverages TAKE Solutions, Clinical Accelerators to reduce ... 50% (when compared to standardization without the accelerators), thus ... At the heart of the ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2
... of the peskiest household pests, while disastrous to homes, could ... Purdue University study. Mike Scharf, the O. Wayne Rollins/Orkin ... has discovered a cocktail of enzymes from the guts of ... that inhibit fuel production from woody biomass. The Scharf Laboratory ...
... A study from the microbiology lab at the Lifespan hospitals ... in identifying Clostridium difficile Toxin ( C. diff ... a molecular method detects up to 50 percent more cases ... technology is more expensive, it allows for more cases to ...
... Speculation that the welfare of a small, ... in part supported by new scientific research, according to a ... Ecosphere , a journal of the Ecological Society of America. ... whose population has plummeted over the last 15 years, has ...
Cached Biology News:Termites' digestive system could act as biofuel refinery 2Not all tests are created equal: Identifying C. diff in hospital labs 2Research bolsters importance of horseshoe crab spawning for migrating shorebirds 2
...
... II identification and library ... module that adds capabilities ... and identification of unknowns ... entries of the same ...
Fingerprinting II cluster analysis is an optional module that adds dendrogram and phylogenetic tree construction, cluster and group significance, and congruence of techniques functions to the Fingerp...
Fingerprinting II Informatix optional matrix types module, is an optional module that adds external similarity and distance matrix functions to the Fingerprinting II Informatix software package....
Biology Products: